Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study

David J. Pinato; Francesco A. Mauri; Paolo Spina; Owen Cain; Abdul Siddique; Robert Goldin; Stephane Victor; Corinna Pizio; Ayse U. Akarca; Renzo L. Boldorini; Luca Mazzucchelli; James R.M. Black; Shishir Shetty; Teresa Marafioti; Rohini Sharma

doi:10.1038/s41416-019-0466-x

Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study

David J. Pinato, Francesco A. Mauri, Paolo Spina, Owen Cain, Abdul Siddique, Robert Goldin, Stephane Victor, Corinna Pizio, Ayse U. Akarca, Renzo L. Boldorini, Luca Mazzucchelli, James R.M. Black, Shishir Shetty, Teresa Marafioti, Rohini Sharma

Dipartimento di Scienze della Salute

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Abstract

Programmed cell death ligand-1 immunohistochemical detection (PD-L1 IHC) is a putative predictor of response to PD-1/PD-L1-targeted checkpoint inhibitors. However, there is no gold standard assay in hepatocellular carcinoma (HCC). We evaluated 5 PD-L1 IHC assay platforms (E1LN3, 28-8, 22c3, SP263 and SP142) in 100 HCCs reporting PD-L1 expression in malignant (M) and tumour-infiltrating immune cells (TICs) and non-tumorous cirrhotic tissues (NTICs). We found substantial inter-assay heterogeneity in detecting PD-L1 expression in M (R² = 0.080–0.921), TICs (Cohen’s κ = 0.175–0.396) and NTICs (κ = 0.004–0.505). Such diversity may impact on the reliability and reproducibility of PD-L1 IHC assays as a predictor of response to immune checkpoint inhibitors.

Lingua originale	Inglese
pagine (da-a)	1033-1036
Numero di pagine	4
Rivista	British Journal of Cancer
Volume	120
Numero di pubblicazione	11
DOI	https://doi.org/10.1038/s41416-019-0466-x
Stato di pubblicazione	Pubblicato - 28 mag 2019

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1038/s41416-019-0466-x

Altri file e collegamenti

Link to publication in Scopus

Cita questo

Pinato, D. J., Mauri, F. A., Spina, P., Cain, O., Siddique, A., Goldin, R., Victor, S., Pizio, C., Akarca, A. U., Boldorini, R. L., Mazzucchelli, L., Black, J. R. M., Shetty, S., Marafioti, T., & Sharma, R. (2019). Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study. British Journal of Cancer, 120(11), 1033-1036. https://doi.org/10.1038/s41416-019-0466-x

@article{66fdc8105377494886392d1bd573ffdc,

title = "Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study",

abstract = "Programmed cell death ligand-1 immunohistochemical detection (PD-L1 IHC) is a putative predictor of response to PD-1/PD-L1-targeted checkpoint inhibitors. However, there is no gold standard assay in hepatocellular carcinoma (HCC). We evaluated 5 PD-L1 IHC assay platforms (E1LN3, 28-8, 22c3, SP263 and SP142) in 100 HCCs reporting PD-L1 expression in malignant (M) and tumour-infiltrating immune cells (TICs) and non-tumorous cirrhotic tissues (NTICs). We found substantial inter-assay heterogeneity in detecting PD-L1 expression in M (R2 = 0.080–0.921), TICs (Cohen{\textquoteright}s κ = 0.175–0.396) and NTICs (κ = 0.004–0.505). Such diversity may impact on the reliability and reproducibility of PD-L1 IHC assays as a predictor of response to immune checkpoint inhibitors.",

author = "Pinato, {David J.} and Mauri, {Francesco A.} and Paolo Spina and Owen Cain and Abdul Siddique and Robert Goldin and Stephane Victor and Corinna Pizio and Akarca, {Ayse U.} and Boldorini, {Renzo L.} and Luca Mazzucchelli and Black, {James R.M.} and Shishir Shetty and Teresa Marafioti and Rohini Sharma",

note = "Publisher Copyright: {\textcopyright} 2019, The Author(s).",

year = "2019",

month = may,

day = "28",

doi = "10.1038/s41416-019-0466-x",

language = "English",

volume = "120",

pages = "1033--1036",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Springer Nature",

number = "11",

}

Pinato, DJ, Mauri, FA, Spina, P, Cain, O, Siddique, A, Goldin, R, Victor, S, Pizio, C, Akarca, AU, Boldorini, RL, Mazzucchelli, L, Black, JRM, Shetty, S, Marafioti, T & Sharma, R 2019, 'Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study', British Journal of Cancer, vol. 120, n. 11, pagg. 1033-1036. https://doi.org/10.1038/s41416-019-0466-x

TY - JOUR

T1 - Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma

T2 - the Blueprint-HCC study

AU - Pinato, David J.

AU - Mauri, Francesco A.

AU - Spina, Paolo

AU - Cain, Owen

AU - Siddique, Abdul

AU - Goldin, Robert

AU - Victor, Stephane

AU - Pizio, Corinna

AU - Akarca, Ayse U.

AU - Boldorini, Renzo L.

AU - Mazzucchelli, Luca

AU - Black, James R.M.

AU - Shetty, Shishir

AU - Marafioti, Teresa

AU - Sharma, Rohini

PY - 2019/5/28

Y1 - 2019/5/28

N2 - Programmed cell death ligand-1 immunohistochemical detection (PD-L1 IHC) is a putative predictor of response to PD-1/PD-L1-targeted checkpoint inhibitors. However, there is no gold standard assay in hepatocellular carcinoma (HCC). We evaluated 5 PD-L1 IHC assay platforms (E1LN3, 28-8, 22c3, SP263 and SP142) in 100 HCCs reporting PD-L1 expression in malignant (M) and tumour-infiltrating immune cells (TICs) and non-tumorous cirrhotic tissues (NTICs). We found substantial inter-assay heterogeneity in detecting PD-L1 expression in M (R2 = 0.080–0.921), TICs (Cohen’s κ = 0.175–0.396) and NTICs (κ = 0.004–0.505). Such diversity may impact on the reliability and reproducibility of PD-L1 IHC assays as a predictor of response to immune checkpoint inhibitors.

AB - Programmed cell death ligand-1 immunohistochemical detection (PD-L1 IHC) is a putative predictor of response to PD-1/PD-L1-targeted checkpoint inhibitors. However, there is no gold standard assay in hepatocellular carcinoma (HCC). We evaluated 5 PD-L1 IHC assay platforms (E1LN3, 28-8, 22c3, SP263 and SP142) in 100 HCCs reporting PD-L1 expression in malignant (M) and tumour-infiltrating immune cells (TICs) and non-tumorous cirrhotic tissues (NTICs). We found substantial inter-assay heterogeneity in detecting PD-L1 expression in M (R2 = 0.080–0.921), TICs (Cohen’s κ = 0.175–0.396) and NTICs (κ = 0.004–0.505). Such diversity may impact on the reliability and reproducibility of PD-L1 IHC assays as a predictor of response to immune checkpoint inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=85065331948&partnerID=8YFLogxK

U2 - 10.1038/s41416-019-0466-x

DO - 10.1038/s41416-019-0466-x

M3 - Article

SN - 0007-0920

VL - 120

SP - 1033

EP - 1036

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 11

ER -

Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study

Abstract

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo